Long-term follow-up evaluates rhIGF-1/rhIGFBP-3 safety and efficacy for Retinopathy of Prematurity prevention
Background
Retinopathy of Prematurity (ROP) is a severe developmental disorder of the retina affecting preterm infants, characterized by abnormal retinal blood vessel proliferation that can lead to vision loss or retinal detachment. Current treatments often involve anti-VEGF therapies, which can have systemic side effects. Insulin-like growth factor-1 (IGF-1) is crucial for normal retinal vessel growth and development. Supplementation with rhIGF-1/rhIGFBP-3 (recombinant human IGF-1 complexed with its binding protein 3) has been explored as a potential strategy to promote healthy retinal development and prevent ROP.
Study Design
This ongoing study is a long-term follow-up of children previously enrolled in Study ROPP-2008-01 (NCT01096784). The original study investigated short-term exposure to rhIGF-1/rhIGFBP-3 versus standard neonatal care for the prevention of ROP. The current research aims to evaluate the long-term efficacy and safety outcomes in these same children, assessing any lasting effects of the initial intervention years after treatment. This design allows for a comprehensive understanding of the intervention's enduring impact.
Why It Matters
Understanding the long-term safety and efficacy of rhIGF-1/rhIGFBP-3 is critical for its potential clinical adoption in preventing Retinopathy of Prematurity (ROP). If this follow-up study demonstrates sustained benefits and an acceptable safety profile, it could inform future treatment protocols for preterm infants. Positive long-term data would support the use of rhIGF-1/rhIGFBP-3 as a foundational therapy, potentially reducing the need for more invasive or systemically impactful interventions like anti-VEGF agents, thereby optimizing visual outcomes and minimizing treatment burden for this vulnerable population.
rhigf-1
igfbp-3
retinopathy of prematurity
rop
pediatric
long-term study